VANCOUVER, British Columbia, Sept. 27, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) ("HYTN” or "the Company”), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabinoids and psilocybin, is pleased to announce, further to its news release dated July 19, 2024, that it has filed a Business Acquisition Report (BAR) in respect of its acquisition of Prism Scientific Labs Inc. The BAR may be found under the Company's profile on SEDAR+ (www.sedarplus.ca).